Foundayo dosing starts at 0.8 mg and steps up over months

The Food and Drug Administration approved Foundayo (orforglipron) on April 1, 2026, for adults with obesity or with overweight and at least one weight-related health condition, to be used along with a reduced-calorie diet and more physical activity ^[1]. The approval sets out a slow, staged dosing schedule: patients start at 0.8 mg once daily, move up to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days, with further optional increases to 9 mg, 14.5 mg and finally 17.2 mg, each step requiring at least 30 days at the prior dose and depending on how a patient responds and tolerates the drug ^[1].

Foundayo is a GLP-1 receptor agonist taken as a tablet rather than an injection, which sets it apart from Ozempic, Wegovy and Mounjaro/Zepbound. According to UK regulators, who authorized the same drug in August 2026, it can be taken at any time of day with no food or water restrictions, unlike oral semaglutide (Rybelsus), which must be taken on an empty stomach ^[2].

The FDA based its decision on two randomized, placebo-controlled trials in adults with obesity or overweight plus a weight-related condition. After 72 weeks, people taking Foundayo alongside diet and exercise changes lost a statistically significant and clinically meaningful amount of body weight compared with those on placebo, the agency said, though it did not release specific percentage figures in its announcement ^[1].

Common side effects listed by the FDA include nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, bloating, fatigue, burping, acid reflux, gas and hair loss ^[1]. The label also carries warnings for pancreatitis, serious gastrointestinal reactions, kidney injury from fluid loss, low blood sugar, allergic reactions, eye damage in people with type 2 diabetes, gallbladder disease, and breathing complications during anesthesia ^[1]. As with other GLP-1 drugs, Foundayo carries a boxed warning about thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2 ^[1]. The FDA also said it should not be combined with another GLP-1 receptor agonist ^[1].

Why it matters for patients

The gradual dose increase is standard practice across this drug class, and it exists specifically to reduce the nausea, vomiting and other digestive side effects that are common when GLP-1 treatment starts too fast ^[1]. For someone starting Foundayo, that means the process of reaching a full dose could take four months or longer, since each of the five possible step-ups requires a minimum 30-day wait ^[1]. Patients who tolerate lower doses well and see the results they want may not need to reach the highest 17.2 mg dose at all, since the schedule allows doctors to base further increases on response and tolerability ^[1].

Because Foundayo is a pill, it removes the need for injections that some patients avoid with Wegovy, Zepbound, Ozempic or Mounjaro, and unlike Rybelsus it does not require fasting before taking it, according to the UK's medicines regulator ^[2]. Whether this makes the drug easier to stick with over many months is not addressed in the sources reviewed here.

What happens next

The FDA approval came through the agency's National Priority Voucher pilot program, arriving just 50 days after the application was filed and roughly 294 days ahead of the drug's original target decision date of January 20, 2027 ^[1]. Eli Lilly and Company, which holds the approval, also submitted Foundayo for a type 2 diabetes indication in the United States during the second quarter of 2026, according to trade reporting, though the FDA has not yet acted on that application ^[2]. In the United Kingdom, the same drug was authorized for weight management and type 2 diabetes in August 2026, though as of that report it was not yet available through the National Health Service pending a separate cost-effectiveness review ^[2].